Patients (pts) with advanced hepatocellular carcinoma (HCC) with long-term response to immune checkpoint inhibitor (ICI) therapy

被引：0
|
作者：
Keane, F. [1 ]
Cowzer, D. [1 ]
Khalil, D. [1 ]
Shia, J. [1 ]
Do, R. [1 ]
Folorunso, S. [1 ]
El Dika, I. [1 ]
Yaqubie, A. [1 ]
Kim, T. [1 ]
O'Reilly, E. [1 ]
Abou-Alfa, G. [2 ,3 ]
Harding, J. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Cornell Univ, Dept Med, Mem Sloan Kettering Canc Ctr, New York, NY USA
[3] Cornell Univ, Weill Med Coll, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.04.328
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-272
引用
收藏
页码：S111 / S112
页数：2
相关论文
共 50 条
  • [1] Outcomes in advanced hepatocellular carcinoma (HCC) patients (pts) treated with immune checkpoint inhibitors (ICI)
    Cowzer, D.
    Capanu, M.
    Keane, F.
    Khalil, D.
    Shia, J.
    Do, R.
    Chou, J.
    Walch, H.
    El Dika, I.
    Yaqubie, A.
    Solit, D.
    Berger, M.
    O'Reilly, E.
    Harding, J.
    Abou-Alfa, G.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S109 - S109
  • [2] Response to multi-targeted kinase inhibitor (MKI) after immune checkpoint inhibitor (ICI) in patients with hepatocellular carcinoma (HCC)
    Chng, S. S. Y.
    Tan, S. W. L.
    Lee, J. J. X.
    Choo, S. P.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [3] Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients
    Tong, Justin
    Kartolo, Adi
    Yeung, Cynthia
    Hopman, Wilma
    Baetz, Tara
    [J]. CURRENT ONCOLOGY, 2022, 29 (10) : 7953 - 7963
  • [4] Clinical Indicators for Long-Term Survival with Immune Checkpoint Therapy in Advanced Hepatocellular Carcinoma
    Monge, Cecilia
    Xie, Changqing
    Steinberg, Seth M.
    Greten, Tim F.
    [J]. JOURNAL OF HEPATOCELLULAR CARCINOMA, 2021, 8 : 507 - 512
  • [5] Predictors of poor response to immune-checkpoint inhibitor (ICI) treatment among patient with hepatocellular carcinoma (HCC)
    Das, Parthib
    Paul, Samuel
    Min, Eric
    Elsaid, Mohamed I.
    Mittra, Arjun
    Malalur, Pannaga G.
    Manne, Ashish
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Long-term toxicities with immune checkpoint inhibitor (ICI) in melanoma patients.
    Tong, Justin
    Kartolo, B. Adi
    Yeung, Cynthia
    Hopman, Wilma M.
    Baetz, Tara D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] Effect of immune checkpoint inhibitor (ICI) treatment in hepatocellular carcinoma (HCC) based on underlying liver disease
    Wu, Linda
    Bagiella, Emilia
    Rudshteyn, Michelle
    Cohen, Deirdre Jill
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [8] Response and outcomes with immune checkpoint inhibitor (ICI) in patients (pts) with urothelial carcinoma (UC) and subtype histology (SH)
    Rafailia Bakaloudi, Dimitra
    Makrakis, Dimitrios
    Talukder, Rafee
    Nikolaos Diamantopoulos, Leonidas
    Jindal, Tanya
    Nguyen, Charles B.
    Hobeika, Charbel
    Thomas, Vinay Mathew
    Johnson, Jeffrey
    Marmolejo Castaneda, David Humberto
    Korolewicz, James
    Zakopoulou, Roubini
    Hui, Gavin
    Barata, Pedro C.
    Alonso Buznego, Lucia Andrea
    Brown, Jason R.
    Stewart, Tyler F.
    Epstein, Ilana B.
    Khaki, Ali Raza
    Grivas, Petros
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Response Prediction in Immune Checkpoint Inhibitor Immunotherapy for Advanced Hepatocellular Carcinoma
    Hung, Hao-Chien
    Lee, Jin-Chiao
    Wang, Yu-Chao
    Cheng, Chih-Hsien
    Wu, Tsung-Han
    Lee, Chen-Fang
    Wu, Ting-Jung
    Chou, Hong-Shiue
    Chan, Kun-Ming
    Lee, Wei-Chen
    [J]. CANCERS, 2021, 13 (07)
  • [10] Combined immune checkpoint inhibition (ICI) with tremelimumab and durvalumab in patients with advanced hepatocellular carcinoma (HCC) or biliary tract carcinomas (BTC).
    Floudas, Charalampos S.
    Xie, Changqing
    Brar, Gagandeep
    Morelli, Maria Pia
    Fioravanti, Suzanne
    Walker, Melissa
    Mabry-Hrones, Donna
    Wood, Brad J.
    Levy, Elliot B.
    Krishnasamy, Venkatesh P.
    Greten, Tim F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
12345